FDG-PET as a predictive biomarker

The mTOR (mammalian target of rapamycin) inhibitor, everolimus, affects tumor growth by targeting cellular metabolic proliferation pathways and delays renal cell carcinoma (RCC) progression.01/28/2014
Source: Kidney Cancer Association - Category: Cancer & Oncology Source Type: news